Delving into the Latest Updates on Quratis, Inc. with Synapse

Overview

Tags

Infectious Diseases

Immune System Diseases

Respiratory Diseases

Vaccine

Therapeutic vaccine

mRNA vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Infectious Diseases	3
Immune System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Vaccine	2
Therapeutic vaccine	2
mRNA vaccine	1

The purpose of this study is to evaluate safety, immunogenicity of ID93+GLA-SE compared to placebo following three intramuscular (IM) injections on Days 0, 28 and 56 in BCG-vaccinated QFT-negative healthy adolescent. The healthy adolescent will all have had the childhood TB vaccine called BCG, and all of them must have a negative result for a blood test for exposure to the bacteria that cause TB (QuantiFERON-TB Gold Plus, or "QFT"). Study participants will be followed for 12 months after the last injection for safety reasons. Blood will be drawn for laboratory tests for safety and immunogenicity tests. The study hypothesis is that the vaccine is safe and immunogenic in this study population.

Start Date02 Apr 2019

Sponsor / Collaborator

Quratis, Inc.Startup

NCT03806686 / Unknown statusPhase 2

A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Explore the Immunogenicity and Efficacy of ID93+GLA-SE Vaccine in BCG-Vaccinated Healthy Healthcare Workers

The purpose of this study is to evaluate the experimental tuberculosis (TB) vaccine called ID93+GLA-SE. The safety, immunogenicity, and efficacy of ID93+GLA-SE will be compared to placebo, after three intramuscular (IM) injections one month apart in healthy healthcare workers. The healthcare workers will all have had the childhood TB vaccine called BCG, and all of them must have a negative result for a blood test for exposure to the bacteria that cause TB (QuantiFERON-TB Gold Plus, or "QFT"). Study participants will be followed for 12 months after the last injection for safety reasons. Blood will be drawn for laboratory tests for safety, immunogenicity, and efficacy tests. Efficacy will be evaluated by further QFT testing. The study hypothesis is that the vaccine is safe, immunogenic, and effective in this study population.

Start Date31 May 2018

Sponsor / Collaborator

Quratis, Inc.Startup

[+1]

100 Clinical Results associated with Quratis, Inc.

Login to view more data

0 Patents (Medical) associated with Quratis, Inc.

Login to view more data

2

Literatures (Medical) associated with Quratis, Inc.

01 Jun 2023·Infectious diseases and therapy

Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.

Article

Author: Cho, Sang-Nae ; Jung, Kwangsoo ; Lee, Boram ; Larsen, Sasha E ; Reese, Valerie A ; Cho, Kwan Goo ; Choi, Jae Chol ; Baldwin, Susan L ; Woo, Yun Ju ; Coler, Rhea N ; Ahn, Eunsol ; Kim, Nan Yul ; Lee, Hyejon ; Kang, Young Ae ; Park, Kwang Joo ; Reed, Steven G ; Ahn, Jun Ho ; Ko, Da Yeon ; Choi, Yu Hwa

INTRODUCTIONThis randomized, double-blind, placebo-controlled, phase 2a trial was conducted to evaluate the safety and immunogenicity of the ID93 + glucopyranosyl lipid adjuvant (GLA)-stable emulsion (SE) vaccine in human immunodeficiency virus (HIV)-negative, previously Bacillus Calmette-Guérin (BCG)-vaccinated, and QuantiFERON-TB-negative healthy adults in South Korea.METHODSAdults (n = 107) with no signs or symptoms of tuberculosis were randomly assigned to receive three intramuscular injections of 2 μg ID93 + 5 μg GLA-SE, 10 μg ID93 + 5 μg GLA-SE, or 0.9% normal saline placebo on days 0, 28, and 56. For safety assessment, data on solicited adverse events (AEs), unsolicited AEs, serious AEs (SAEs), and special interest AEs were collected. Antigen-specific antibody responses were measured using serum enzyme-linked immunosorbent assay. T-cell immune responses were measured using enzyme-linked immunospot and intracellular cytokine staining.RESULTSNo SAEs, deaths, or AEs leading to treatment discontinuation were found. The solicited local and systemic AEs observed were consistent with those previously reported. Compared with adults administered with the placebo, those administered with three intramuscular vaccine injections exhibited significantly higher antigen-specific antibody levels and Type 1 T-helper cellular immune responses.CONCLUSIONThe ID93 + GLA-SE vaccine induced antigen-specific cellular and humoral immune responses, with an acceptable safety profile in previously healthy, BCG-vaccinated, Mycobacterium tuberculosis-uninfected adult healthcare workers.TRIAL REGISTRATIONThis clinical trial was retrospectively registered on 16 January 2019 at Clinicaltrials.gov (NCT03806686).

Journal of Veterinary Science

Combined antimicrobial effect of two peptide nucleic acids against Staphylococcus aureus and S. pseudintermedius veterinary isolates

Article

Author: Lee, Jun Bong ; Yoon, Jang Won ; Kim, Se Kye ; Lee, Hyung Tae

BACKGROUNDStaphylococcus aureus and S. pseudintermedius are the major etiological agents of staphylococcal infections in humans, livestock, and companion animals. The misuse of antimicrobial drugs has led to the emergence of antimicrobial-resistant Staphylococcus spp., including methicillin-resistant S. aureus (MRSA) and methicillin-resistant S. pseudintermedius (MRSP). One novel therapeutic approach against MRSA and MRSP is a peptide nucleic acid (PNA) that can bind to the target nucleotide strands and block expression. Previously, two PNAs conjugated with cell-penetrating peptides (P-PNAs), antisense PNA (ASP)-cmk and ASP-deoD, targeting two essential genes in S. aureus, were constructed, and their antibacterial activities were analyzed.OBJECTIVESThis study analyzed the combined antibacterial effects of P-PNAs on S. aureus and S. pseudintermedius clinical isolates.METHODSS. aureus ATCC 29740 cells were treated simultaneously with serially diluted ASP-cmk and ASP-deoD, and the minimal inhibitory concentrations (MICs) were measured. The combined P-PNA mixture was then treated with S. aureus and S. pseudintermedius veterinary isolates at the determined MIC, and the antibacterial effect was examined.RESULTSThe combined treatment of two P-PNAs showed higher antibacterial activity than the individual treatments. The MICs of two individual P-PNAs were 20 and 25 μM, whereas that of the combined treatment was 10 μM. The application of a combined treatment to clinical Staphylococcus spp. revealed S. aureus isolates to be resistant to P-PNAs and S. pseudintermedius isolates to be susceptible.CONCLUSIONSThese observations highlight the complexity of designing ASPs with high efficacy for potential applications in treating staphylococcal infections in humans and animals.

100 Deals associated with Quratis, Inc.

Login to view more data

100 Translational Medicine associated with Quratis, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

Phase 1 Clinical

Phase 2 Clinical

1

4

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

QTP101	Tuberculosis More	Phase 2
QTP102	Tuberculosis More	Phase 1 Clinical
QTP-104	COVID-19 More	Phase 1
Cancer(Quratis)	Neoplasms More	Preclinical
Autoimmune disorder(Quratis)	Autoimmune Diseases More	Preclinical